Malin Corporation PLC traded at 7.60 this Tuesday March 24th, decreasing 0.10 or 1.30 percent since the previous trading session. Looking back, over the last four weeks, Malin Corporation lost 1.30 percent. Over the last 12 months, its price fell by 26.21 percent. Looking ahead, we forecast Malin Corporation PLC to be priced at 7.47 by the end of this quarter and at 6.81 in one year, according to Trading Economics global macro models projections and analysts expectations.
Malin Corporation plc is an Ireland-based global life sciences company. The Company's businesses include Altan, which is an injectable drug company; AN2H Discovery Limited, which focuses on designing novel small molecule therapeutics; Emba Medical Limited, which offers vascular embolization system; Emba Neuro Limited; Hatteras Venture Partners (HVP), which is a life sciences company; Immunocore, which is a biotechnology company; Jaan Health, which is a healthcare mobile technology company; Melinta Therapeutics, Inc.; Novan, Inc., which is a clinical stage company; Poseida Therapeutics, Inc., which is a human therapeutics company, and Viamet Pharmaceuticals, Inc., which is a drug discovery company. The Company operates through subsidiaries, and focuses on various therapeutic areas, including dermatology, anti-infective, pain, immunology, oncology, neurology, anatomy and other areas.